Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Subject with Multiple Sclerosis eligible for enrolment in the study must meet all of the following 1. Provision of written informed consent to participate in this study 2. Patients diagnosed as relapsing remitting multiple sclerosis based on modified McDonald in 2017 3. Relape must have been confirmed by a neurologist at least twice within 24 months, or once within 12 months before enrollment 4. Have at least one T2 lesion on MRI scans at screening 5. EDSS less than or equal to 7 6. 20 =< Age < 65 7. Promise to prevent conception for at least 90 days after the last administration 8. Neurological stability has been confirmed by a neurologist  Subject with MS patients meeting any of the following must not be enrolled in the study: 1. Diagnosed as Neuromyelitis Optica 2. Women who are pregnant or lactating 3. Patients who is prohibited MRI 4. Patients who are allergic to Gd-contrast medium 5. History of liver diseases or liver transplantation 6. Liver dysfunction in the screening test and baseline physical examination 7. History of cancer past five years 8. Negative for herpes zoster virus antibody 9. Positive for Syphilis serum reaction 10. Positive for Beta-glucan or positive for T-spot 11. Positive for Anti-Aquaporin 4 antibody 12. History of HIV infection 13. History of HBV or HCV infection 14. History of Transplantation 15. Use of any other investigational agents and/or experimental agents within 4 months prior to the first anticipated administration of study medication. 16. History of blood donation (200 ml within 2 months, 400 ml within 3 months) prior to the first anticipated administration of study medication 17. Lymphocyte number < 600 /mm3 in peripheral blood 18. Current diagnosed or suspected infectious diseases 19. Compromised Patients 20. Inflammatory Bowel disease 21. Subjects with prolongation of QT/QTc interval 22. History or have risk of torsade de pointes 23. Taking the medicine which has risk of prolongation of QT/QTc interval 24. History of severe allergy of medicine or food 25. History or current of drug/ alcohol addiction 26. Bronchial Asthma 27. Epilepsy Other protocol-defined